Preclinical and early clinical data of ZN-1041, a best-in-class BBB penetrable HER2 inhibitor to treat breast cancer with CNS metastases

Authors
Category Primary study
JournalJournal of Clinical Oncology
Year 2023
This article has no abstract
Epistemonikos ID: 58cd6350832ba992151d019c1f8b472607ef5a4a
First added on: Feb 16, 2025